Mechanisms of the placebo effect in pain and psychiatric disorders

Pharmacogenomics Journal

Volumn 16, Issue 6, 2016, Pages 491-500

  Holmes, R D ^a   Tiwari, A K ^a   Kennedy, J L ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; OPIATE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ANALGESIA; ANXIETY DISORDER; DEPRESSION; DIABETIC NEUROPATHY; FIBROMYALGIA; GENETICS; HUMAN; MAJOR DEPRESSION; MIGRAINE; NEUROBIOLOGY; NEUROPATHIC PAIN; OSTEOARTHRITIS; PAIN; PHENOTYPE; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL PHOBIA; TRANQUILIZING ACTIVITY; WOUND; ANIMAL; ANXIETY DISORDERS; CONTROLLED CLINICAL TRIAL (TOPIC); GENOTYPE; PATHOPHYSIOLOGY; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; PROCEDURES; PSYCHOLOGY;

ANIMALS; ANXIETY DISORDERS; CONTROLLED CLINICAL TRIALS AS TOPIC; DEPRESSION; GENOTYPE; HUMANS; PAIN; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; PHENOTYPE; PLACEBO EFFECT; PLACEBOS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84977275967     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2016.15     Document Type: Review

References (133)

1. Pepper OH. A note on the placebo. Am J Pharm 1945; 117: 409-412.
2. Raicek JE, Stone BH, Kaptchuk TJ. Placebos in 19th century medicine: a quantitative analysis of the BMJ. BMJ 2012; 345: e8326.
3. Beecher H. The powerful placebo. J Am Med Assoc 1955; 159: 1602-1606.
4. Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336: 999-1003.
5. Khan A, Detke M, Khan SRF, Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis 2003; 191: 211-218.
6. Alphs L, Benedetti F, Fleischhacker WW, Kane JM. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?. Int J Neuropsychopharmacol 2012; 15: 1003-1014.
7. Faria V, Fredrikson M, Furmark T. Imaging the placebo response: a neurofunctional review. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2008; 18: 473-485.
8. Lidstone SCC, Stoessl AJ. Understanding the placebo effect: contributions from neuroimaging. Mol Imaging Biol MIB Off Publ Acad Mol Imaging 2007; 9: 176-185.
9. Kokkotou E, Conboy LA, Ziogas DC, Quilty MT, Kelley JM, Davis RB et al. Serum correlates of the placebo effect in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 285-e81.
10. Kaddurah-Daouk R, Bogdanov MB, Wikoff WR, Zhu H, Boyle SH, Churchill E et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl Psychiatry 2013; 3: e223.
11. Cordero P, Ashley EA. Whole-genome sequencing in personalized therapeutics. Clin Pharmacol Ther 2012; 91: 1001-1009.
12. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-Analysis of randomised controlled trials. Ann Rheum Dis 2008; 67: 1716-1723.
13. Irizarry MC, Webb DJ, Ali Z, Chizh BA, Gold M, Kinrade FJ et al. Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. Clin J Pain 2009; 25: 469-476.
14. Häuser W, Bartram-Wunn E, Bartram C, Reinecke H, Tölle T. Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors. Pain 2011; 152: 1709-1717.
15. Kamper SJ, Machado LAC, Herbert RD, Maher CG, McAuley JH. Trial methodology and patient characteristics did not influence the size of placebo effects on pain. J Clin Epidemiol 2008; 61: 256-260.
16. Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia Int J Headache 2005; 25: 124-131.
17. Lasagna L, Mosteller F, Von Felsinger JM, Beecher HK. A study of the placebo response. Am J Med 1954; 16: 770-779.
18. Kelley JM, Lembo AJ, Ablon JS, Villanueva JJ, Conboy LA, Levy R et al. Patient and practitioner influences on the placebo effect in irritable bowel syndrome. Psychosom Med 2009; 71: 789-797.
19. Morton DL, Watson A, El-Deredy W, Jones AKP. Reproducibility of placebo analgesia: effect of dispositional optimism. Pain 2009; 146: 194-198.
20. Geers AL, Helfer SG, Kosbab K, Weiland PE, Landry SJ. Reconsidering the role of personality in placebo effects: dispositional optimism, situational expectations, and the placebo response. J Psychosom Res 2005; 58: 121-127.
21. Geers AL, Wellman JA, Fowler SL, Helfer SG, France CR. Dispositional optimism predicts placebo analgesia. J Pain Off J Am Pain Soc 2010; 11: 1165-1171.
22. Schweinhardt P, Seminowicz DA, Jaeger E, Duncan GH, Bushnell MC. The anatomy of the mesolimbic reward system: a link between personality and the placebo analgesic response. J Neurosci 2009; 29: 4882-4887.
23. Peciña M, Azhar H, Love TM, Lu T, Fredrickson BL, Stohler CS et al. Personality trait predictors of placebo analgesia and neurobiological correlates. Neuropsychopharmacology 2013; 38: 639-646.
24. de Moor MHM, Costa PT, Terracciano A, Krueger RF, de Geus EJC, Toshiko T et al. Meta-Analysis of genome-wide association studies for personality. Mol Psychiatry 2012; 17: 337-349.
25. Kaptchuk TJ, Kelley JM, Deykin A, Wayne PM, Lasagna LC, Epstein IO et al. Do ?placebo responders? exist?. Contemp Clin Trials 2008; 29: 587-595.
26. Whalley B, Hyland ME, Kirsch I. Consistency of the placebo effect. J Psychosom Res 2008; 64: 537-541.
27. Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet 1978; 2: 654-657.
28. Benedetti F, Amanzio M, Maggi G. Potentiation of placebo analgesia by proglumide. Lancet 1995; 346: 1231.
29. Benedetti F, Amanzio M, Rosato R, Blanchard C. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat Med 2011; 17: 1228-1230.
30. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-Activated opioid systems versus conditioning-Activated specific subsystems. J Neurosci 1999; 19: 484-494.
31. Eippert F, Bingel U, Schoell ED, Yacubian J, Klinger R, Lorenz J et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 2009; 63: 533-543.
32. Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ et al. Placeboinduced changes in fMRI in the anticipation and experience of pain. Science 2004; 303: 1162-1167.
33. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia-imaging a shared neuronal network. Science 2002; 295: 1737-1740.
34. Zubieta J-K, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA et al. Placebo effects mediated by endogenous opioid activity on μ-opioid receptors. J Neurosci 2005; 25: 7754-7762.
35. Wager TD, Scott DJ, Zubieta J-K. Placebo effects on human mu-opioid activity during pain. Proc Natl Acad Sci USA 2007; 104: 11056-11061.
36. Eippert F, Finsterbusch J, Bingel U, Büchel C. Direct evidence for spinal cord involvement in placebo analgesia. Science 2009; 326: 404-404.
37. Stein N, Sprenger C, Scholz J, Wiech K, Bingel U. White matter integrity of the descending pain modulatory system is associated with interindividual differences in placebo analgesia. Pain 2012; 153: 2210-2217.
38. Colloca L, Klinger R, Flor H, Bingel U. Placebo analgesia: psychological and neurobiological mechanisms. Pain 2013; 154: 511-514.
39. Wager TD, Atlas LY, Leotti LA, Rilling JK. Predicting individual differences in placebo analgesia: contributions of brain activity during anticipation and pain experience. J Neurosci 2011; 31: 439-452.
40. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta J-K. Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 2007; 55: 325-336.
41. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta J-K. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008; 65: 220-231.
42. Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB et al. Catechol-Omethyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PloS One 2012; 7: e48135.
43. Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, McInerney-Leo A, Nussbaum R et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 2005; 8: 594-596.
44. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917-6922.
45. Dávila W, Basterreche N, Arrue A, Zamalloa MI, Gordo E, Dávila R et al. The influence of the Val158Met catechol-O-methyltransferase polymorphism on the personality traits of bipolar patients. PloS One 2013; 8: e62900.
46. Yacubian J, Sommer T, Schroeder K, Gläscher J, Kalisch R, Leuenberger B et al. Gene-gene interaction associated with neural reward sensitivity. Proc Natl Acad Sci USA 2007; 104: 8125-8130.
47. Krogsbøll LT, Hróbjartsson A, Gøtzsche PC. Spontaneous improvement in randomised clinical trials: meta-Analysis of three-Armed trials comparing no treatment, placebo and active intervention. BMC Med Res Methodol 2009; 9: 1.
48. Smolka MN, Schumann G, Wrase J, Grüsser SM, Flor H, Mann K et al. Catechol-Omethyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J Neurosci Off J Soc Neurosci 2005; 25: 836-842.
49. Ballard IC, Murty VP, Carter RM, MacInnes JJ, Huettel SA, Adcock RA. Dorsolateral prefrontal cortex drives mesolimbic dopaminergic regions to initiate motivated behavior. J Neurosci Off J Soc Neurosci 2011; 31: 10340-10346.
50. Luijten M, Veltman DJ, Hester R, Smits M, Pepplinkhuizen L, Franken IHA. Brain activation associated with attentional bias in smokers is modulated by a dopamine antagonist. Neuropsychopharmacology 2012; 37: 2772-2779.
51. Peciña M, Martínez-Jauand M, Love T, Heffernan J, Montoya P, Hodgkinson C et al. Valence-specific effects of BDNF Val66Met polymorphism on dopaminergic stress and reward processing in humans. J Neurosci Off J Soc Neurosci 2014; 34: 5874-5881.
52. Chen Z-Y, Patel PD, Sant G, Meng C-X, Teng KK, Hempstead BL et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-Type BDNF in neurosecretory cells and cortical neurons. J Neurosci Off J Soc Neurosci 2004; 24: 4401-4411.
53. Peciña M, Love T, Stohler CS, Goldman D, Zubieta J-K. Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures. Neuropsychopharmacology 2015; 40: 957-965.
54. Nees F, Witt SH, Dinu-Biringer R, Lourdusamy A, Tzschoppe J, Vollstädt-Klein S et al. BDNF Val66Met and reward-related brain function in adolescents: role for early alcohol consumption. Alcohol 2015; 49: 103-110.
55. Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 2007; 103: 77-87.
56. Sia AT, Lim Y, Lim ECP, Goh RWC, Law HY, Landau R et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008; 109: 520-526.
57. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 2001; 293: 311-315.
58. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lötsch J. The mu-opioid receptor gene polymorphism 118A4G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 2006; 16: 625-636.
59. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 2002; 121: 173-190.
60. Gardner EL, Vorel SR. Cannabinoid transmission and reward-related events. Neurobiol Dis 1998; 5: 502-533.
61. Welch SP. Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry Abingdon Engl 2009; 21: 143-151.
62. Peciña M, Martínez-Jauand M, Hodgkinson C, Stohler CS, Goldman D, Zubieta JK. FAAH selectively influences placebo effects. Mol Psychiatry 2014; 19: 385-391.
63. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98: 9371-9376.
64. Clement AB, Hawkins EG, Lichtman AH, Cravatt BF. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci Off J Soc Neurosci 2003; 23: 3916-3923.
65. Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?. Schizophr Bull 2010; 36: 504-509.
66. Volavka J, Cooper TB, Laska EM, Meisner M. Placebo washout in trials of antipsychotic drugs. Schizophr Bull 1996; 22: 567-576.
67. Mallinckrodt CH, Tamura RN, Tanaka Y. Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials. J Psychiatr Res 2011; 45: 1202-1207.
68. Agid O, Siu CO, Potkin SG, Kapur S, Watsky E, Vanderburg D et al. Metaregression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry 2013; 170: 1335-1344.
69. Khan A, Yavorsky WC, Liechti S, DiClemente G, Rothman B, Opler M et al. Assessing the sources of unreliability (rater, subject, time-point) in a failed clinical trial using items of the Positive and Negative Syndrome Scale (PANSS). J Clin Psychopharmacol 2013; 33: 109-117.
70. Welge JA, Keck Jr. P.E. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacology (Berl) 2003; 166: 1-10.
71. Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials: A meta-Analysis. JAMA Psychiatry 2014; 71: 1409-1421.
72. Averbuch M, Katzper M. Gender and the placebo analgesic effect in acute pain. Clin Pharmacol Ther 2001; 70: 287-291.
73. Dager SR, Khan A, Cowley D, Avery DH, Elder J, Roy-Byrne P et al. Characteristics of placebo response during long-Term treatment of panic disorder. Psychopharmacol Bull 1990; 26: 273-278.
74. Marques TR, Arenovich T, Agid O, Sajeev G, Muthén B, Chen L et al. The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychol Med 2011; 41: 1481-1488.
75. Potkin S, Agid O, Siu C, Watsky E, Vanderburg D, Remington G. Placebo response trajectories in short-Term and long-Term antipsychotic trials in schizophrenia. Schizophr Res 2011; 132: 108-113.
76. Benedetti F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol 2008; 48: 33-60.
77. de la Fuente-Fernández R, Schulzer M, Stoessl AJ. Placebo mechanisms and reward circuitry: clues from Parkinson?s disease. Biol Psychiatry 2004; 56: 67-71.
78. Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE. Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol 2009; 29: 372-377.
79. Mavissakalian MR, Jones B, Olson S. Absence of placebo response in obsessivecompulsive disorder. J Nerv Ment Dis 1990; 178: 268-270.
80. Huppert JD, Schultz LT, Foa EB, Barlow DH, Davidson JRT, Gorman JM et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. Am J Psychiatry 2004; 161: 1485-1487.
81. Rosenberg NK, Mellergård M, Rosenberg R, Beck P, Ottosson JO. Characteristics of panic disorder patients responding to placebo. Acta Psychiatr Scand Suppl 1991; 365: 33-38.
82. Furmark T, Appel L, Henningsson S, Ahs F, Faria V, Linnman C et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci Off J Soc Neurosci 2008; 28: 13066-13074.
83. Coryell W, Noyes R. Placebo response in panic disorder. Am J Psychiatry 1988; 145: 1138-1140.
84. Woodman CL, Noyes R Jr, Ballenger JC, Lydiard RB, Sievers G, Mihalko D. Predictors of response to alprazolam and placebo in patients with panic disorder. J Affect Disord 1994; 30: 5-13.
85. Hackett D, Haudiquet V, Salinas E. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-Term treatment of patients with generalised anxiety disorder. Eur Psychiatry J Assoc Eur Psychiatr 2003; 18: 182-187.
86. Schweizer E, Rickels K. Placebo response in generalized anxiety: its effect on the outcome of clinical trials. J Clin Psychiatry 1997; 58 (Suppl 11): 30-38.
87. Rosenberg R. Prediction of placebo response in panic disorder: a short review. Nord J Psychiatry 1994; 48: 153-158.
88. Rapaport MH, Pollack M, Wolkow R, Mardekian J, Clary C. Is placebo response the same as drug response in panic disorder?. Am J Psychiatry 2000; 157: 1014-1016.
89. Domschke K, Dannlowski U. Imaging genetics of anxiety disorders. NeuroImage 2010; 53: 822-831.
90. Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson K, Ingvar M. Placebo in emotional processing-induced expectations of anxiety relief activate a generalized modulatory network. Neuron 2005; 46: 957-969.
91. Faria V, Appel L, Åhs F, Linnman C, Pissiota A, Frans O et al. Amygdala subregions tied to SSRI and placebo response in patients with social anxiety disorder. Neuropsychopharmacology 2012; 37: 2222-2232.
92. Benedetti F, Carlino E, Pollo A. How placebos change the patient?s brain. Neuropsychopharmacology 2011; 36: 339-354.
93. Furmark T, Tillfors M, Garpenstrand H, Marteinsdottir I, Långström B, Oreland L et al. Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci Lett 2004; 362: 189-192.
94. Brown SM, Peet E, Manuck SB, Williamson DE, Dahl RE, Ferrell RE et al. A regulatory variant of the human tryptophan hydroxylase-2 gene biases amygdala reactivity. Mol Psychiatry 2005; 10: 884-888.
95. Potter WZ, Demitrack MA, DeBrota DJ, Faries D, Herrera J. Controlling the placebo response rates in depression. Eur Neuropsychopharmacol 1998; 8 (Supplement 2): S80-S81.
96. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L et al. The placebo effect in irritable bowel syndrome trials: a meta-Analysis. Neurogastroenterol Motil 2005; 17: 332-340.
97. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome?. A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009; 19: 34-40.
98. Entsuah R, Vinall P. Potential predictors of placebo response: lessons from a large database. Drug Inf J 2007; 41: 315-330.
99. Wilcox CS, Cohn JB, Linden RD, Heiser JF, Lucas PB, Morgan DL et al. Predictors of placebo response: a retrospective analysis. Psychopharmacol Bull 1992; 28: 157-162.
100. Fairchild CJ, Rush AJ, Vasavada N, Giles DE, Khatami M. Which depressions respond to placebo?. Psychiatry Res 1986; 18: 217-226.
101. Sheline YI, Black KJ, Bardgett ME, Csernansky JG. Platelet binding characteristics distinguish placebo responders from nonresponders in depression. Neuropsychopharmacology 1995; 12: 315-322.
102. Leuchter AF, Morgan M, Cook IA, Dunkin J, Abrams M, Witte E. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology (Berl) 2004; 177: 15-22.
103. Brown WA, Dornseif BE, Wernicke JF. Placebo response in depression: a search for predictors. Psychiatry Res 1988; 26: 259-264.
104. Brown WA, Johnson MF, Chen MG. Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res 1992; 41: 203-214.
105. Katon W, Russo J, Frank E, Barrett J, Williams JW Jr, Oxman T et al. Predictors of nonresponse to treatment in primary care patients with dysthymia. Gen Hosp Psychiatry 2002; 24: 20-27.
106. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-Analysis of data submitted to the food and drug administration. PLoS Med 2008; 5: e45.
107. Gomeni R, Merlo-Pich E. Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. Br J Clin Pharmacol 2007; 63: 595-613.
108. Nelson JC, Zhang Q, Deberdt W, Marangell LB, Karamustafalioglu O, Lipkovich IA. Predictors of remission with placebo using an integrated study database from patients with major depressive disorder. Curr Med Res Opin 2012; 28: 325-334.
109. Bialik RJ, Ravindran AV, Bakish D, Lapierre YD. A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci 1995; 20: 265-270.
110. Lee S, Walker JR, Jakul L, Sexton K. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials?. A meta-Analytic evaluation. Depress Anxiety 2004; 19: 10-19.
111. Trivedi MH, Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?. Neuropsychopharmacolopgy 1994; 11: 33-43.
112. Greenberg RP, Fisher S, Riter JA. Placebo washout is not a meaningful part of antidepressant drug trials. Percept Mot Skills 1995; 81: 688-690.
113. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 2004; 29: 566-579.
114. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-Analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol 2006; 26: 56-60.
115. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72: 115-127.
116. Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M et al. A doubleblind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 2012; 81: 87-97.
117. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002; 159: 122-129.
118. Tiwari AK, Zai CC, Sajeev G, Arenovich T, Müller DJ, Kennedy JL. Analysis of 34 candidate genes in bupropion and placebo remission. Int J Neuropsychopharmacol 2012: 1-11.
119. Kranz GS, Kasper S, Lanzenberger R. Reward and the serotonergic system. Neuroscience 2010; 166: 1023-1035.
120. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78: 804-814.
121. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009; 9: 225-233.
122. Buckholtz JW, Meyer-Lindenberg A. MAOA and the neurogenetic architecture of human aggression. Trends Neurosci 2008; 31: 120-129.
123. Pavlov KA, Chistiakov DA, Chekhonin VP. Genetic determinants of aggression and impulsivity in humans. J Appl Genet 2012; 53: 61-82.
124. Zubieta J-K, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y et al. COMT val158met Genotype Affects μ-Opioid Neurotransmitter Responses to a Pain Stressor. Science 2003; 299: 1240-1243.
125. Brody AL, Mandelkern MA, Olmstead RE, Scheibal D, Hahn E, Shiraga S et al. Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry 2006; 63: 808-816.
126. Jutkiewicz EM, Roques BP. Endogenous Opioids as Physiological Antidepressants: Complementary Role of Delta Receptors and Dopamine. Neuropsychopharmacology 2012; 37: 303-304.
127. Zhang H, Torregrossa MM, Jutkiewicz EM, Shi Y-G, Rice KC, Woods JH et al. Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through d-And μ-opioid receptors independent of antidepressant-like effects. Eur J Neurosci 2006; 23: 984-994.
128. Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials?. Results from pooled and meta-Analyses. J Clin Psychiatry 2010; 71: 270-279.
129. Tedeschini E, Fava M. Goodness TM, Papakostas GI. Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: A meta-Analysis. Eur Neuropsychopharmacol 2010; 20: 562-567.
130. Stewart PA, Cameron T, Farb RI. Functional Neuroanatomy. 2012, Illustrated by Kevin Millar. Retrieved from http://fn.med.utoronto.ca/.
131. Cohen D, Consoli A, Bodeau N, Purper-Ouakil D, Deniau E, Guile J-M et al. Predictors of placebo response in randomized controlled trials of psychotropic drugs for children and adolescents with internalizing disorders. J Child Adolesc Psychopharmacol 2010; 20: 39-47.
132. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002; 22: 40-45.
133. Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B. Which factors predict placebo response in anxiety disorders and major depression?. An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 2006; 67: 1741-1746.